• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Palvella Therapeutics Inc.

    11/13/25 5:31:00 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PVLA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Palvella Therapeutics, Inc.

    (Name of Issuer)


    Common stock, $0.001 par value per share

    (Title of Class of Securities)


    697947109

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    697947109


    1Names of Reporting Persons

    SUVRETTA CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    822,400.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    822,400.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    822,400.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.4 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    697947109


    1Names of Reporting Persons

    AVERILL MASTER FUND, LTD.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    714,463.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    714,463.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    714,463.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.5 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    697947109


    1Names of Reporting Persons

    AARON COWEN
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    822,400.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    822,400.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    822,400.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.4 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Palvella Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    125 Strafford Avenue, Suite 360, Wayne, Pennsylvania 19087
    Item 2. 
    (a)Name of person filing:

    Suvretta Capital Management, LLC Averill Master Fund, Ltd. Aaron Cowen
    (b)Address or principal business office or, if none, residence:

    Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022
    (c)Citizenship:

    Suvretta Capital Management, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
    (d)Title of class of securities:

    Common stock, $0.001 par value per share
    (e)CUSIP No.:

    697947109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Suvretta Capital Management, LLC - 822,400 Averill Master Fund, Ltd. - 714,463 Aaron Cowen - 822,400
    (b)Percent of class:

    Suvretta Capital Management, LLC - 7.4% Averill Master Fund, Ltd. - 6.5% Aaron Cowen - 7.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (ii) Shared power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 822,400 Averill Master Fund, Ltd. - 714,463 Aaron Cowen - 822,400

     (iii) Sole power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 822,400 Averill Master Fund, Ltd. - 714,463 Aaron Cowen - 822,400

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, Ltd., may be deemed to beneficially own more than 5% of the Common stock, $0.001 par value per share.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SUVRETTA CAPITAL MANAGEMENT, LLC
     
    Signature:By: /s/ Andrew Nathanson
    Name/Title:Andrew Nathanson, General Counsel and Chief Compliance Officer
    Date:11/13/2025
     
    AVERILL MASTER FUND, LTD.
     
    Signature:By: /s/ Andrew Nathanson
    Name/Title:Andrew Nathanson, Authorized Signatory
    Date:11/13/2025
     
    AARON COWEN
     
    Signature:By: /s/ Aaron Cowen
    Name/Title:Aaron Cowen
    Date:11/13/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
    Exhibit Information

    [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

    Get the next $PVLA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PVLA

    DatePrice TargetRatingAnalyst
    11/19/2025$143.00Outperform → Strong Buy
    Raymond James
    9/9/2025$85.00Outperform
    Oppenheimer
    8/6/2025$54.00Outperform
    Raymond James
    7/21/2025$56.00Buy
    Truist
    4/9/2025$50.00Buy
    Chardan Capital Markets
    3/26/2025$45.00Buy
    Stifel
    3/7/2025$50.00Sector Outperform
    Scotiabank
    2/20/2025$39.00Buy
    Canaccord Genuity
    More analyst ratings

    $PVLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $51,720 worth of shares (4,000 units at $12.93), increasing direct ownership by 2% to 180,671 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    12/19/24 10:23:28 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Palvella's recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025 Top-line results for fully enrolled Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations remain on track for the first quarter of 2026 Expanded QTORIN™ rapamycin's development into clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FD

    11/11/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

    WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 4:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archiv

    11/6/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

    DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients QTORIN™ pitavastatin has the potential to be the first pathogenesis-directed therapy designed to directly inhibit the mevalonate pathway, the causal driver of DSAP, in the pathogenic skin tissue Company plans to initiate a Phase 2 trial evaluating QTORIN™ pitavastatin for DSAP in the second half of 2026 Company to host webcast conference call today, November 5, 2025 at 8:30am ET WAYNE, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (

    11/5/25 6:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Palvella Therapeutics upgraded by Raymond James with a new price target

    Raymond James upgraded Palvella Therapeutics from Outperform to Strong Buy and set a new price target of $143.00

    11/19/25 8:47:27 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Palvella Therapeutics with a new price target

    Oppenheimer initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $85.00

    9/9/25 7:43:25 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Palvella Therapeutics with a new price target

    Raymond James initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $54.00

    8/6/25 8:01:45 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PVLA
    SEC Filings

    View All

    Chief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $370,965 worth of shares (4,302 units at $86.23) (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    11/21/25 4:25:25 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wessel Tadd S.

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 8:00:08 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kiritsy Christopher P

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    6/11/25 7:59:56 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Palvella Therapeutics Inc.

    SCHEDULE 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    11/14/25 4:19:50 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Palvella Therapeutics Inc.

    SCHEDULE 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

    11/13/25 5:31:00 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Palvella Therapeutics Inc.

    10-Q - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    11/12/25 8:33:15 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Financials

    Live finance-specific insights

    View All

    Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Palvella's recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies Top-line results for fully enrolled Phase 2 TOIVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for cutaneous venous malformations remain on track for mid-December 2025 Top-line results for fully enrolled Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations remain on track for the first quarter of 2026 Expanded QTORIN™ rapamycin's development into clinically significant angiokeratomas, a rare and debilitating lymphatic disease with no FD

    11/11/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

    DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients QTORIN™ pitavastatin has the potential to be the first pathogenesis-directed therapy designed to directly inhibit the mevalonate pathway, the causal driver of DSAP, in the pathogenic skin tissue Company plans to initiate a Phase 2 trial evaluating QTORIN™ pitavastatin for DSAP in the second half of 2026 Company to host webcast conference call today, November 5, 2025 at 8:30am ET WAYNE, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (

    11/5/25 6:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

    WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies, today announced that it will report its third quarter 2025 financial results before market open on Tuesday, November 11, 2025. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast of the call with slides, please click here or visit the "Events & Presentations" sec

    11/4/25 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

    Ms. Kline to lead Palvella's commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong genetic disease affecting an estimated more than 30,0000 patients in the U.S., if approved Under Kline's leadership at Dompé, Oxervate®, a first-in-disease topical therapy for rare disease neurotrophic keratitis, scaled to over $500 million in annual U.S. sales while achieving early profitability WAYNE, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing an

    5/27/25 8:00:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care